Cytokine gene-modified vaccines in the therapy of cancer

Pharmacology and Therapeutics

Volumn 69, Issue 1, 1996, Pages 1-14

  Bubeník, Jan ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

cancer; cytokines; gene transfer; vaccines

Indexed keywords

CANCER VACCINE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

CANCER; CANCER PATIENT; CELLULAR IMMUNITY; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; MELANOMA; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0030067255     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(95)02016-0     Document Type: Review

References (204)

1. Abdel-Wahab, Z., Li, W.-P., Osanto, S., Darrow, T. L., Hessling, J., Vervaert, C. E., Burrascano, M., Barber, J. and Seigler, H. F. (1994a) Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell. Immunol. 159: 26-39.
2. Abdel-Wahab, Z. A., Osanto, S., Darrow, T. L., Barber, J. R., Vervaert, C. E., Gangavalli, R., McCallister, T. J. and Seigler, H. F. (1994b) Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. Cancer Gene Ther. 1: 171-179.
3. Agarwala, S. S. and Kirkwood, J. M. (1994) Interferons in the therapy of solid tumors. Oncology 51: 129-136.
4. Aggarwal, B. B., Kohr, W. J., Hass, W. J., Moffat, B., Spencer, S. A., Henzel, P. E., Bringman, T. S., Nedwin, G. E., Goeddel, D. V. and Harkins, R. N. (1985) Human tumor necrosis factor: production, purification, and characterization. J. Biol. Chem. 260: 2345-2354.
5. Alexander, R. B. and Rosenberg, S. A. (1991) Tumor necrosis factor: clinical aplications. In: Biologic Therapy of Cancer, pp. 378-392, De Vita, V. T., Jr., Hellman, S. and Rosenberg, S. A. (eds.) Lippincott, Philadelphia.
6. Allison, M. A. K., Jones, S. E. and McGuffey, P. (1989) Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukaemia and selected solid tumours. J. Clin. Oncol. 7: 75-80.
7. Anderson, S. K. (1992) Molecular cloning of human and murine natural killer cell tumor recognition proteins. In: NK Cell Mediated Cytotoxicity: Receptors, Signaling and Mechanisms, pp. 2-14, Lotzová, E. and Herberman, R. B. (eds.) CRC Press, Boca Raton.
8. Andrews, J. V. R., Schoof, D. D., Bertagnolli, M. M., Peoples, G. E., Goedegebuure, P. S. and Eberlein, T. J. (1993) Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J. Immunother. 14: 1-10.
9. Aoki, T., Tashiro, K., Miyatake, S. I., Kinashi, T., Nakano, T., Oda, Y., Kikuchi, H. and Honjo, T. (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA 89: 3850-3854.
10. Asher, A. L., Mulé, J. J., Kasid, A., Restifo, N. P., Salo, J. C., Reichert, C. M., Jaffe, G., Fendly, B., Kriegler, M. and Rosenberg, S. A. (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J. Immunol. 146: 3227-3234.
11. Balemans, L. T. M., Steerenberg, P. A., Koppenhagen, F. J., Kremer, B. H. A., De Mulder, P. H. M., Claessen, A. M. E., Scheper, R. J. and Den Otter, W. (1994) PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophoshamide. Int. J. Cancer 58: 871-876.
12. Banchereau, J., Defrance, T., Galizzi, J. P., Miossee, P. and Rousset, F. (1991) Human interleukin 4. Bull. Cancer 78: 299-306.
13. Belldegrun, A., Tso, C.-L., Sakata, T., Duckett, T., Brunda, M. J., Barsky, S. H., Chai, J., Kaboo, R., Lavey, R. S., McBride, W. H. and deKernion, J. B. (1993) Human renal carcinoma line transfected with interleukin-2 and/or interferon α genes(s): implications for live cancer vaccines. J. Natl. Cancer Inst. 85: 207-216.
14. Beutler, B. and Cerami, A. (1988) Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518.
15. Blankenstein, T. (1994) Increasing tumour immunogenicity by genetic modification. Eur. J. Cancer 30A: 1182-1187.
16. Blankenstein, T., Qin, Z., Überla, K., Müller, W., Rosen, H., Volk, H.-D. and Diamantstein, T. (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med. 173: 1047-1052.
17. Bock, S. N., Cameron, R. B., Kragel, P., Mulé, J. J. and Rosenberg, S. A. (1991) Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice. Cancer Res. 51: 2649-2654.
18. Boon, T. (1992) Toward a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58: 177-210.
19. Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P. and Van Pel, H. (1994) Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12: 337-365.
20. Borden, E. C. and Sondel, P. M. (1990) Lymphokines and cytokines as cancer treatment. Cancer 65: 800-814.
21. Bosco, M., Giovarelli, M., Forni, M., Modesti, A., Scarpa, S., Masuelli, L. and Forni, G. (1990) Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J. Immunol. 145: 3136-3143.
22. Boussiotis, V. A., Gribben, J. G., Freeman, G. J. and Nadler, L. M. (1994) Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr. Opin. Immunol. 6: 794-807.
23. Bronchud, M. H. (1994) Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: five years on. Oncology 51: 189-197.
24. Brunda, M. J. and Gately, M. K. (1994) Antitumor activity of interleukin-12. Clin. Immunol. Immunopathol. 71: 253-255.
25. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F. and Gately, M. K. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178: 1223-1230.
26. Bubeník, J. (1989) Local immunotherapy of cancer with interleukin 2. Immunol. Lett. 21: 267-274.
27. Bubeník, J. (1990) Local and regional immunotherapy of cancer with interleukin 2. J. Cancer Res. Clin. Oncol. 116: 1-7.
28. Bubeník, J. (1993a) IL-2 gene therapy of cancer: at its beginning. Folia Biol. (Praha) 39: 279-288.
29. Bubeník, J. (1993b) IL-2 and gene therapy of cancer. Int. J. Oncol. 2: 1049-1052.
30. Bubeník, J. (1994) Utilization of IL-2 and IL-2 gene transfer for regional immunotherapy of cancer. In: Cytokine-Induced Tumor Immunogenicity, pp. 113-130, Forni, G., Foa, R., Santoni, A. and Frati, L. (eds.) Academic Press, London.
31. Bubeník, J., Perlmann, P., Indrová, M., Šímová, J., Jandlová, T. and Neuwirt J. (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol. Immunother. 14: 205-206.
32. Bubeník, J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubeníková, D., Šímová, J. and Jandlová, T. (1988) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19: 279-282.
33. Bubeník, J., Šímová, J. and Jandlová, T. (1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23: 287-292.
34. Bubeník, J., Lotzová, E., Indrová, M., Šímová, J., Jandlová, T. and Bubeníková, D. (1992) Use of IL-2 gene transfer in local immunotherapy of cancer. Cancer Lett. 62: 257-262.
35. Bubeník, J., Šímová, J., Bubeníková, D., Zeuthen, J. and Indrová, M. (1995) Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J. Cancer Res. Clin. Oncol. 121: 39-43.
36. Bukowski, R. M., Goodman, P. and Crawford, E. D. (1990) Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest oncology group study. J. Natl. Cancer Inst. 82: 143-146.
37. Canellos, G. P. (1985) Interferon in the treatment of malignant lymphoma. Semin. Oncol. 12: 25-29.
38. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670.
39. Case, D., Sonneborn, H. L., Paul, S. D., Hiebel, J., Boyd, M. A., Shepp, M. A., Dorsk, B. M. and Bonnem, E. (1986) Phase II study of rDNA alpha-2 interferon in patients with multiple myeloma using an escalation induction phase. Cancer Treat. Rep. 70: 1251-1254.
40. Cebon, J. S. and Lieschke, G. J. (1994) Granulocyte-macrophage colony-stimulating factor for cancer treatment. Oncology 51: 177-188.
41. Chazen, G. D., Pereira, G. M. B., Le Gros, G., Gillis, S. and Shevach, E. M. (1989) Interleukin 7 is a T-cell growth factor. Proc. Natl. Acad. Sci. USA 86: 5923-5927.
42. Cohen, A., Petsche, D., Grunberger, T. and Freedman, M. H. (1992) Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line. Leuk. Res. 16: 751-760.
43. Connor, J., Bannerji, R., Saito, S., Heston, W., Fair, W. and Gilboa, E. (1993) Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med. 177: 1127-1134.
44. Cordier, L., Duffour, M.-T., Sabourin, J.-C., Lee, M. G., Cabannes, J., Ragot, T., Perricaudet, M. and Haddada, H. (1995) Complete recovery of mice from a preestablished tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 2: 16-21.
45. Cortesina, G., De Stefani, A., Giovarelli, M., Baroglio, M. G., Cavallo, G. P., Jemma, C. and Forni, G. (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62: 2482-2485.
46. Crawford, R. P., Finbloom, D. S., Ohara, J., Paul, W. E. and Meltzer, M. S. (1987) B cell stimulatory factor-1 (interleukin 4) activated macrophages for increased tumoricidal activity and expression of Ia antigens. J. Immunol. 139: 135-141.
47. Creekmore, S. P., Harris, J. E. and Ellis, T. M. (1989) A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusion. J. Clin. Oncol. 7: 276-284.
48. Defrance, T., Vandervliet, B., Aubry, J. P., Takebe, Y., Arai, N., Miyajima, A., Yokota, T., Lee, F., Arai, K. J., De Vries, J. E. and Banchereau, J. (1987) B cell growth-promoting activity of recombinant human interleukin 4. J. Immunol. 139: 1135-1141.
49. Dillman, R. O., Church, C., Oldham, R. K., West, W. H., Schwartzberg, L. and Birch, R. (1992) Inpatient continuous infusion interleukin-2 in 788 patients with cancer. Cancer 71: 2358-2370.
50. Dinarello, C. A. (1994) The biological properties of interleukin-1. Eur. Cytokine Netw. 5: 517-531.
51. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R. C. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90: 3539-3543.
52. Eisenthal, A., Kashtan, H., Rabau, M., Rama-Krishna, V., Chaitchik, S. and Skornick, Y. (1993) Antitumor effect of recombinant interleukin-6 expressed in eukaryotic cells. Cancer Immunol. Immunother. 36: 101-107.
53. Fan, D., O'Brian, C. A., Ioannides, C. G. and Clyne, R. K. (1991) Granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of cancer. In Vivo 5: 571-578.
54. Farhood, H., Gao, X., Son, K., Yang, Y.-Y., Lazo, J. S. and Huang, L. (1994) Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann. NY Acad. Sci. 716: 23-35.
55. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. J., Simons, J. W., Karasuyama, H., Vogelstein, B. and Frost, P. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403.
56. 1-Interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells. Cancer Res. 53: 1107-1112.
57. Foa, R., Guarini, A. and Gansbacher, B. (1992) IL 2 treatment for cancer: from biology to gene therapy. Br. J. Cancer 66: 992-998.
58. Foa, R., Guarini, A., Cignetti, A., Cronin, K., Rosenthal, F. and Gansbacher, B. (1994) Cytokine gene therapy: a new strategy for the management of cancer patients. Nat. Immun. 13: 67-75.
59. Foon, K., Doroshow, J., Bonnem, E., Fefer, A., Graham, S., Grosh, B., Narayan, P., Elias, L., Harvey, H., Schulof, R., Williams, R., Rinehart, J., Zekan, P., Catalona, W., Dillman, R., Salmon, S. and Galasso, F. (1988) A prospective randomized trial of α2B-interferon/γ-interferon or the combination in advanced metastatic renal cell carcinoma. J. Biol. Response Modif. 7: 540-545.
60. Galagher, G. and Zaloom, Y. (1992) Peritumoral IL-4 treatment induces systemic inhibition of tumour growth in experimental melanoma. Anticancer Res. 12: 1019-1024.
61. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K. and Gilboa, E. (1990a) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50: 7820-7825.
62. Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R. and Gilboa, E. (1990b) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172: 1217-1224.
63. Gansbacher, B., Zier, K., Cronin, K., Hantzopoulos, P. A., Bouchard, B., Houghton, A., Gilboa, E. and Golde, D. (1992) Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817-2825.
64. Garrido, F. and Ruiz-Cabello, F. (1991) MHC expression on human tumors - its relevance for local tumor growth and metastasis. Semin. Cancer Biol. 2: 3-10.
65. Gastl, G., Finstad, C. L., Guarini, A., Bosl, G., Gilboa, E., Bander, N. H. and Gansbacher, B. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 52: 6229-6236.
66. Gelmann, E. P., Preble, O. T., Steis, R., Lane, H. C., Rook, A. H., Wesley, M., Jacob, J., Fauci, A., Masur, H. and Longo, D. (1985) Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical response and prognostic parameters. Am. J. Med. 78: 737-741.
67. Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P. and Dexter, T. M. (1992) Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections - A phase I dose toxicity trial. Br. J. Cancer 66: 204-210.
68. Gisselbrecht, C., Maraninchi, D., Pico, J. L., Milpied, N., Coiffier, B., Divine, M., Tiberghiem, P., Bosly, A., Tilly, H., Boulat, O. and Brandely, M. (1994) Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 83: 2081-2085.
69. Goldstein, D. and Laszlo, J. (1988) The role of interferon in cancer therapy: a current perspective. Cancer J. Clin. 38: 258-277.
70. Golumbek, P. T., Lazenby, A. J., Levitsky, H. J., Jaffee, L. M., Karasuyama, H., Baker, M. and Pardoll, D. M. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716.
71. Goodwin, R. G. and Namen, A. E. (1990) The cloning and characterization of interleukin 7. In: The Year in Immunology, pp. 127-139, Cruse, J. M. and Lewis, R. E. (eds.) S. Karger, Basel.
72. Gresser, J. and Tovey, M. G. (1978) Antitumor effects of interferon. Biochim. Biophys. Acta 516: 231-247.
73. Grimm, E. A., Mazumder, A., Zhang, H. Z. and Rosenberg, S. A. (1982) Lymphokine activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823-1841.
74. Groopman, J. E., Molina, J.-M. and Scadden, D. T. (1989) Hematopoietic growth factors. Biology and clinical applications. N. Engl. J. Med. 321: 1449-1459.
75. Gutterman, J. U. (1994) Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 91: 1198-1205.
76. Gutterman, J. U., Blumenschein, A. R., Alexanian, R., Yap, H.-Y., Buzdar, A. U., Cabanillas, F., Hortobagyi, G. N., Hersh, E. M., Rasmunssen, S. L., Harmon, M., Kramer, M. and Pestka, S. (1980) Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann. Intern. Med. 93: 399-406.
77. Herberman, R. B. and Gorelik, E. (1989) Role of the natural immune system in control of primary tumors and metastasis. In: Functions of the Natural Immune System, pp. 3-37, Reynolds, C. W. and Wiltrout, R. H. (eds.) Plenum Publishing Corporation, New York.
78. Herberman, R. B., Hiserodt, J., Vujanovic, N., Balch, C., Lotzová, E., Bolhuis, R., Golub, S., Lanier, L. L., Phillips, J. H., Riccardi, C., Ritz, J., Santoni, A., Schmidt, R. E. and Uchida, A. (1987) Lymphokine-activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol. Today 8: 178-181.
79. Hersey, P., Hasic, E., MacDonald, M., Edwards, A., Spurling, A., Coates, A. S., Milton, G. W. and McCarthy, W. H. (1985) Effects of recombinant interferon on tumor growth and immune responses in patients with metastatic melanoma. Br. J. Cancer 51: 815-826.
80. Hieber, U. and Heim, M. E. (1994) Tumor necrosis factor for the treatment of malignancies. Oncology 51: 142-153.
81. Hinuma, S., Naruo, K., Ootsu, K., Houkan, T., Shiho, O. and Tsukamoto, K. (1987) Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. Immunology 60: 173-179.
82. Hirano, T. (1992) Role of interleukin 6 in autoimmunity and plasma cell neoplasias. In: Concise Reviews in Clinical and Experimental Hematology, pp. 189-201, Murphy, M. J. (ed.) AlphaMed Press, Dayton.
83. Hirano, T., Akira, S., Taga, T. and Kishimoto, T. (1990) Biological and clinical aspects of interleukin 6. Immunol. Today 11: 443-449.
84. Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamantstein, T. and Blankenstein, T. (1993) Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. USA 90: 2774-2778.
85. Huland, E. and Huland, H. (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res. 49: 5469-5474.
86. Iho, S., Shau, H. and Golub, S. H. (1991) Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function. Cell. Immunol. 135: 66-77.
87. Isaacs, A. and Lindenmann, J. (1957) Virus interference: 1. The interferon. Proc. R. Soc. Lond. B 147: 258-267.
88. Jacobs, A. D., Champlin, R. T. and Golde, D. W. (1985) Recombinant alpha-2-interferon for hairy cell leukemia. Blood 65: 1017-1020.
89. Janssen, R. A. J., Mulder, N. H., The, T. H. and de Leij, L. (1994) The immunobiological effects of interleukin-2 in vivo. Cancer Immunol. Immunother. 39: 207-216.
90. Jenkins, M. K. (1994) The ups and downs of T cell costimulation. Immunity 1: 443-446.
91. Jicha, D. L., Mulé, J. J. and Rosenberg, S. A. (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174: 1511-1515.
92. Jones, E. Y., Stuart, D. I. and Walker, N. P. C. (1989) Structure of tumor necrosis factor. Nature 338: 225-228.
93. Karasuyama, H., Tohyama, N. and Tada, T. (1989) Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J. Exp. Med. 169: 13-25.
94. Katz, A., Shulman, L. M., Porgador, A., Revel, M., Feldman, M. and Eisenbach, L. (1993) Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. J. Immunother. 13: 98-109.
95. Kedar, E. and Klein, E. (1992) Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res. 59: 245-322.
96. Keilholz, U., Schlottmann, K., Dummer, R., Link, H., Gulbins, E., Steinhausen, M. and Hunstein, W. (1993) Mechanism and clinical management of interleukin-2-induced renal toxicity and fluid retention. Int. J. Immunopathol. Pharmacol. 6: 1-11.
97. Kirchner, H. (1984) Interferons, a group of multiple lymphokines. Springer Semin. Immunopathol. 7: 347-374.
98. Kirkwood, J. M. and Ernstoff, M. (1985) Melanoma: therapeutic options with recombinant interferons. Semin. Oncol. 12: 7-12.
99. Komschlies, K. L., Gregorio, T. A., Gruys, M. E., Back, T. C., Faltynek, C. R. and Wiltrout, R. H. (1994) Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J. Immunol. 152: 5776-5784.
100. Konno, H., Yamashita, A., Tadakuma, T. and Sakaguchi, S. (1991) Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2. Biotherapy 3: 211-218.
101. Krim, M. (1980a) Towards tumor therapy with interferons, part I. Interferons: production and properties. Blood 55: 711-721.
102. Krim, M. (1980b) Towards tumor therapy with interferons, part II. Interferons: in vivo effects. Blood 55: 875-884.
103. Krown, S. E., Burk, M. W., Kirkwood, J. M., Kerr, D., Morton, D. L. and Oettgen, H. F. (1984) Human leukocyte (alpha) interferon in metastatic malignant melanoma: The American Cancer Society Phase II trial. Cancer Treat. Rep. 68: 723-726.
104. Kuiper, H. M., De Jong, R., Lammers, K., Wijdenes, J. and van Lier, R. A. W. (1994) Influence of CD28 co-stimulation on cytokine production is mainly regulated via interleukin-2. Immunology 83: 38-44.
105. Le, J. and Vilcek, J. (1987) Biology of disease. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab. Invest. 56: 234-248.
106. Legha, S. S., Papadopoulos, N. E. J. and Plager, C. (1987) Clinical evaluation of recombinant Interferon alpha 2A in metastatic melanoma using two different schedules. J. Clin. Oncol. 5: 1240-1246.
107. Ley, V., Langlade-Demoyen, P., Kourilsky, P. and Larsson-Sciard, E. L. (1991) Interleukin 2 dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 21: 851-854.
108. Lienard, D., Ewalenko, P., Delmotte, J.-J., Renard, N. and Lejeune, F. J. (1992) High dose recombinant tumor necrosis factor alpha in combination with interferon-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10: 52-60.
109. Lienard, D., Eggermont, A. M. M., Schraffordt, K. H. and Lejeune, F. J. (1993) High dose of rTNFα, rIFNγ and melphalan in isolation perfusion produce 90% complete response in melanoma metastases. In: Tumor Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance, pp. 233-238, Fiers, W. and Buurma, W. A. (eds.) Karger, Basel.
110. Lollini, P.-L., DeGiovanni, C., Nicoletti, G., Bontadini, A., Tazzari, P. L., Landuzzi, L., Scotlandi, K. and Nanni, P. (1990) Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin. Exp. Metastasis 8: 215-224.
111. Lotze, M. T. and Rosenberg, S. A. (1991) Interleukin-2: clinical applications. In: Biologic Therapy of Cancer, pp. 159-177, De Vita, V. T., Jr., Hellman, S. and Rosenberg, S. A. (eds.) J. B. Lippincott, Philadelphia.
112. Lotze, M. T., Chang, A. E., Seipp, C. A., Simpson, C., Vetto, J. T. and Rosenberg, S. A. (1986) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. JAMA 256: 3117-3124.
113. Lu, L., Zhou, Z., Wu, B., Xiao, M., Shen, R.-N., Williams, D. E., Kin, Y.-J., Kwon, B. S., Ruscetti, S. and Broxmeyer, H. E. (1992) Influence of recombinant human interleukin (IL)-7 on disease progression in mice infected with Friend virus complex. Int. J. Cancer 52: 261-265.
114. Lynch, D. H. and Miller, R. E. (1990) Induction of murine lymphokine-activated killer cells by recombinant IL-7. J. Immunol. 145: 1983-1990.
115. Lynch, D. H., Namen, A. E. and Miller, R. E. (1991) In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur. J. Immunol. 21: 2977-2985.
116. Maas, R. A., Van Weering, D. H. J., Dullens, H. F. J. and Den Otter, W. (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol. Immunother. 33: 389-394.
117. Maekawa, R., Matsumoto, M., Kitagawa, T., Harada, M. and Sato, K. (1986) Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563. Cancer Immunol. Immunother. 23: 25-30.
118. Marincola, F. M., Venzon, D., White, D., Rubin, J. T., Lotze, M. T., Simonis, T. B., Balkissoon, J., Rosenberg, S. A. and Parkinson, D. R. (1992) HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res. 52: 6561-6566.
119. McBride, W. H., Thacker, J. D., Comora, S., Economon, J. S., Kelley, D., Hogge, D., Dubinett, S. M. and Dougherty, G. J. (1992) Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res. 52: 3931-3937.
120. Mier, J. W., Vachino, G., Robert, N. J., Karp, D. D., O'Brien, K. and Atkins, M. B. (1991) Phase I evaluation of three daily intravenous bolus interleukin 4 (IL-4). Proc. Am. Soc. Clin. Oncol. 10: 210-214.
121. Miyamoto, T. and Wu, S. (1990) Antitumor activity of recombinant human interleukin-1 against heterotransplanted human nonHodgkin lymphomas in nude mice. Jpn. J. Cancer Res. 81: 1175-1183.
122. Morstyn, G. and Burgess, A. W. (1988) Hemopoietic growth factors: a review. Cancer Res. 48: 5624-5637.
123. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. and Coffman, R. L. (1986) Two types of murine helper T-cell clone. 1. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136: 2348-2356.
124. Mulé, J. J. and Rosenberg, S. A. (1991) Interleukin-2: preclinical trials. In: Biologic Therapy of Cancer, pp. 142-158, De Vita, V. T., Jr., Hellman, S. and Rosenberg, S. A. (eds.) J. B. Lippincott, Philadelphia.
125. Mulé, J. J., Smith, C. A. and Rosenberg, S. A. (1987) Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J. Exp. Med. 166: 792-797.
126. Mullen, C. A., Coale, M. M., Levy, A. T., Stetler-Stevenson, W. G., Liotta, L. A., Brandt, S. and Blaese, R. M. (1992) Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res. 52: 6020-6024.
127. Mulligan, R. C. (1993) The basic science of gene therapy. Science 260: 926-932.
128. Muss, H. B., Costanzi, J. J., Leavitt, R., Wiliams, R. D., Kempf, R. A., Pollard, R., Ozer, H., Zekan, P. J., Grunberg, S. M., Mitchell, M. S., Coponera, M., Gavigan, M., Ernest, M. L., Venturi, C., Greiner, J. and Spiegel, R. J. (1987) Recombinant alpha interferon in renal cell carcinoma: a randomized trial of two routes of administration. J. Clin. Oncol. 5: 286-291.
129. Nakamura, Y., Wakimoto, H., Abe, J., Kanegae, Y., Saito, I., Aoyagi, M., Hirakawa, K. and Hamada, H. (1994) Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res. 54: 5757-5760.
130. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J. and Lotze, M. T. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697-1706.
131. Niedhart, J. A., Gagen, M. M., Young, D., Tuttle, R., Melink, T. J., Ziccarrelli, A. and Kisner, D. (1984) Interferon-therapy of renal cancer. Cancer Res. 44: 4140-4143.
132. Ohira, T., Ohe, Y., Heike, Y., Podack, E. R., Olsen, K. J., Nishio, K., Nishio, M., Miyahara, Y., Funayama, Y., Ogasawara, H., Arioka, H., Kunikane, H., Fukuda, M., Kato, H. and Saijo, N. (1994) In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant. J. Cancer Res. Clin. Oncol. 120: 631-635.
133. Ohno, R., Kodera, Y. and Ogura, M. (1985) Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon. Cancer Chemother. Pharmacol. 14: 34-37.
134. Old, L. J. (1990) Tumor necrosis factor. In: Tumor Necrosis Factor: Structure, Mechanisms of Action, Role in Disease and Therapy, pp. 1-30, Bonavida, B. and Granger, G. (eds.) S. Karger, Basel.
135. Oppenheim, J. J., Kovacs, E. J., Matsushima, K. and Durum, S. K. (1986) There is more than one interleukin 1. Immunol. Today 7: 45-56.
136. Palladino, M. H., Jr., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., DeLeo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., Liggitt, D. and Patton, J. S. (1987) Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor specific immunity. J. Immunol. 138: 4023-4032.
137. Palmer, P. A., Vinke, J., Evers, P., Pourreau, C., Oskam, R., Roerst, G., Vlems, F., Becker, L., Loriaux, E. and Franks, C. R. (1992) Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur. J. Cancer 28A: 1038-1044.
138. Parkinson, D. R. (1988) Interleukin-2 in cancer therapy. Semin. Oncol. 15 (Suppl. 6): 10-26.
139. Parkinson, D. R., Abrams, J. S., Wiernik, P. H., Rayner, A. A., Margolin, K. A., Van Echo, D. A., Sznol, M., Dutcher, J. P., Aronson, F. R., Doroshow, J. H., Atkins, M. B. and Hawkins, M. J. (1990) Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J. Clin. Oncol. 8: 1650-1656.
140. Paul, W. E. and Ohara, J. (1987) B-cell stimulatory factor-1/interleukin 4. Annu. Rev. Immunol. 5: 429-459.
141. Pizza, G., Severini, G., Menniti, D., De Vinci, C. and Corrado, F. (1984) Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer 34: 359-367.
142. Porgador, A., Tzehoval, E., Katz, A., Vadai, E., Revel, M., Feldman, M. and Eisenbach, L. (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 52: 3679-3686.
143. Porgador, A., Bannerji, R., Watanabe, Y., Feldman, M., Gilboa, E. and Eisenbach, L. (1993a) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol. 150: 1458-1470.
144. Porgador, A., Gansbacher, B., Bannerji, R., Tzehoval, E., Gilboa, E., Feldman, M. and Eisenbach, L. (1993b) Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Int. J. Cancer 53: 471-477.
145. Porgador, A., Tzehoval, E., Vadai, E., Feldman, M. and Eisenbach, L. (1993c) Immunotherapy via gene therapy. Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes. J. Immunother. 14: 191-201.
146. Pyrhönen, S., Konri, M., Holsti, L. R. and Cantell, K. (1992) Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 49: 22-26.
147. Quesada, J. R., Hersh, E. M., Manning, J., Reuben, J., Keating, M., Schnipper, E., Itri, L. and Gutterman, J. V. (1986a) Treatment of hairy cell leukemia (HCL) with recombinant α-interferon. Blood 68: 493-497.
148. Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R. and Gutterman, J. U. (1986b) Clinical toxicity of interferon in cancer patients: a review. J. Clin. Oncol. 4: 234-243.
149. Ratain, M. J., Golomb, H. M., Vardiman, J. W., Vokes, E. E., Jacobs, R. H. and Daly, K. (1985) Prolonged treatment of advanced hairy cell leukemia with recombinant α-2 interferon. Blood 65: 644-648.
150. Raz, E., Watanabe, A., Baird, S. M., Eisenberg, R. A., Parr, T. B., Lotz, M., Kipps, T. J. and Carson, D. A. (1993) Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA 90: 4523-4527.
151. Real, F. X., Oettgen, H. F. and Krown, S. E. (1986) Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte α interferon. J. Clin. Oncol. 4: 544-551.
152. Reiter, Z. (1993) Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity. Crit. Rev. Immunol. 13: 1-34.
153. Restifo, N. P., Spiess, P. J., Karp, S. E., Mulé, J. J. and Rosenberg, S. A. (1992) A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J. Exp. Med. 175: 1423-1431.
154. 2 responses: a key role for the "natural" immune response? Immunol. Today 13: 379-381.
155. 2 subsets: "Eppur si muove!" Eur. Cytokine Netw. 5: 7-12.
156. Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M. and Schwarz, S. L. (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med. 161: 1169-1188.
157. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., Seipp, C. A., Simpson, C. G. and White, D. E. (1987) A progress report on the treatment
158. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A. and White, D. E. (1989) Experience with the use of high dose interleukin-2 based therapies in the treatment of 652 patients with cancer. Ann. Surg. 210: 474-485.
159. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. E. and Seinberg, S. M. (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632.
160. Rossi, A. R., Pericle, F., Rashleigh, S., Janiec, J. and Djeu, J. Y. (1994) Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin 2 and interleukin 12. Blood 83: 1323-1328.
161. Rousset, F., De Waal Malefijt, R., Slierendregt, B., Aubry, J. P., Bonnefoy, J., de France, T., Banchereau, J. and De Vries, J. E. (1988) Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and INF γ. J. Immunol. 140: 2625-2631.
162. Rutten, V. P. M. G., Klein, W. R., De Jong, W. A. C., Misdorp, W., Den Otter, W., Steerenberg, P. A., De Jong, W. H. and Ruitenberg, E. J. (1989) Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. Cancer Immunol. Immunother. 30: 165-169.
163. Saito, S., Bannerji, R., Gansbacher, B., Rosenthal, F. M., Romanenko, P., Heston, W. D. W., Fair, W. R. and Gilboa, E. (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 54: 3516-3520.
164. Sarraf, C. E. (1994) Tumor necrosis factor and cell death in tumours (Review). Int. J. Oncol. 5: 1333-1339.
165. Scheringa, M., Keizer, A., Jeekel, J. and Marquet, R. L. (1989) Anti-tumor effect of recombinant murine TNF-alpha (rMuTNFα) given by continuous i.v. infusion as compared to repeated i.v. injections in a rat liver metastasis model. Int. J. Cancer 43: 905-909.
166. Sheppard, B. C., Venzon, D., Fraker, D. L., Langstein, H. N., Jensen, C. J. and Norton, J. A. (1990) Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor. Cancer Res. 50: 3928-3933.
167. Sleijfer, D. T., Janssen, R. A. J., Buter, J., de Vries, E. G. E., Willemse, P. H. B. and Mulder, N. H. (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol. 10: 1119-1123.
168. Smith, K. A. (1988) Interleukin 2: inception, impact and implications. Science 240: 1169-1176.
169. Sobol, R. E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T. A. and Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2: 164-167.
170. Sohmura, Y., Nakata, K., Yoshida, H., Kashimoto, S., Matsui, Y. and Furuichi, H. (1986) Recombinant human tumor necrosis factor II. Antitumor effect on murine and human tumors transplanted in mice. Int. J. Immunopharmacol. 8:357-368.
171. Soiffer, R. J., Robertson, M. J., Murray, C., Cochran, K. and Ritz, J. (1993) Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 82: 2790-2796.
172. Sosman, J. A., Kohler, P. C., Hank, J., Moore, K. H., Bechhofer, R., Storer, B. and Sondel, P. M. (1988) Repetitive weekly cycles of interleukin 2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J. Natl. Cancer Inst. 80: 1451-1461.
173. Spits, H., Yssel, H., Takabe, Y., Arai, N., Yokota, T., Lee, F., Arai, K. J., Banchereau, J. and De Vries, J. E. (1987) Recombinant interleukin 4 promotes the growth of human T cells. J. Immunol. 139: 1142-1147.
174. Spriggs, D. R. and Yates, S. W. (1992) Experiences with TNF administration in humans. In: Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, pp. 383-406, Bentler, B. (ed.) Raven Press, New York.
175. Steits, R. G., Van der Malen, L. A., Longo, D. L., Clark, J. W., Smith, J. W., Ropp, W. C., Ruscetti, F. W., Creekmore, S. P., Elwood, L. J., Hursey, J. and Urba, W. J. (1990) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. J. Natl. Cancer Inst. 82: 697-703.
176. Stötter, H., Custer, M. C., Bolton, E. S., Guedez, L. and Lotze, M. T. (1991) IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J. Immunol. 146: 150-155.
177. Tahara, H. and Lotze, M. T. (1995) Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 2: 96-106.
178. Tahara, H., Zeh, H. J., III, Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P. D. and Lotze, M. T. (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
179. Takizawa, H., Ohtoshi, T., Ohta, K., Yamashita, N., Hirohata, S. and Hirai, K. (1993) Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 53: 4175-4181.
180. Talmage, J. E. (1988) Therapeutic potential of cytokines: a comparison of preclinical and clinical studies. Prog. Exp. Tumor Res. 32: 154-173.
181. Taniguchi, T. and Minami, Y. (1993) The IL-2/IL-2 receptor system: a current overview. Cell 73: 5-8.
182. Tepper, R. J., Pattengale, P. K. and Leder, P. (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512.
183. Tepper, R. J., Coffman, R. L. and Leder, P. (1992) An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257: 548-551.
184. Teramura, Y., Watanabe, Y., Kan, N., Masuda, T. and Kuribayashi, K. (1993) Interferon-γ-producing tumor induces host tumor-specific T cell responses. Jpn. J. Cancer Res. 84: 689-696.
185. Te Velde, A. A., Klomp, J. P. G., Yard, B. A., De Vries, J. E. and Figdor, C. G. (1988) Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J. Immunol. 140: 1548-1554.
186. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1994) Interferon α2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukaemia. N. Engl. J. Med. 330: 820-825.
187. Thompson, J. A., Brady, J., Kidd, P. and Fefer, A. (1982) Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. Cancer Treat. Rep. 69: 791-793.
188. Toi, M., Bicknell, R. and Harris, A. L. (1992) Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 52: 275-279.
189. Tomazic, V. J., Farha, M., Loftus, A. and Elias, E. G. (1988) Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J. Immunol. 140: 4056-4061.
190. Topp, M. S., Koenigsmann, M., Mire-Sluis, A., Oberberg, D., Eitelbach, F., von Marschall, Z., Notter, M., Reufi, B., Stein, H., Thiel, E. and Berdel, W. E. (1993) Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood 82: 2837-2844.
191. Tourani, J.-M., Levy, V., Briere, J., Levy, R., Franks, C. and Andrieu, J.-M. (1991) Interleukin-2 therapy for refractory and relapsing lymphomas. Eur. J. Cancer 27: 1676-1680.
192. Tsai, S.-C. J., Gansbacher, B., Tait, L., Miller, F. R. and Heppner, G. H. (1993) Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl. Cancer Inst. 85: 546-553.
193. Tunru, I. S., Suzuki, H. and Kobayashi, M. (1993) Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4. Experientia 49: 76-79.
194. Uckert, W. and Walther, W. (1994) Retrovirus-mediated gene transfer in cancer therapy. Pharmacol. Ther. 63: 323-347.
195. Urabe, A. (1994) Interferons for the treatment of hematological malignancies. Oncology 51: 137-141.
196. Vaage, J. (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res. 47: 4296-4298.
197. van Gameren, M. M., Willemse, P. H. B., Mulder, N. H., Limburg, P. C., Groen, H. J. M., Vellenga, E. and de Vries, E. G. E. (1994) Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84: 1434-1441.
198. Vieweg, J., Rosenthal, F. M., Bannerji, R., Heston, W. D. W., Fair, W. R., Gansbacher, B. and Gilboa, E. (1994) Immunotherapy of prostate cancer in the Durnning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54: 1760-1765.
199. Vile, R. and Russel, S. J. (1994) Gene transfer technologies for the gene therapy of cancer. Gene Ther. 1: 88-98.
200. Volberding, P., Valero, R., Rothman, J. and Gee, G. (1984) Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann. NY Acad. Sci. 437: 439-447.
201. Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E.-I., Taniyama, T. and Sakata, T.-A. (1989) Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl. Acad. Sci. USA 86: 9456-9460.
202. Widmer, M. B. and Grabstein, K. H. (1987) Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 326: 795-798.
203. Widmer, M. B., Acres, R. B., Sassenfield, N. M. and Grabstein, K. H. (1987) Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). J. Exp. Med. 166: 1447-1455.
204. Yu, J. S., Wei, M. X., Chiocca, A., Martuza, R. L. and Tepper, R. I. (1993) Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 53: 3125-3128.